an drug prices swing an election? Is every quarter a “great quarter“? And why is everyone freaking out about CRISPR?
We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation with cancer patient and drug pricing advocate David Mitchell about his group’s work to target pharma in the midterm elections. Then we’ll dig into everything you need to know ahead of a busy earnings season for the drug industry. STAT’s Sharon Begley stops by to explain the latest concerns over CRISPR — and why it has brought out such internet vitriol. And finally we’ll talk about the financial well-being of Martin Shkreli’s drug company, a surprising move from the Trump administration, and the year’s biggest biotech IPO.